Mesenchymal stem cells have been shown to mediate immunomodulatory effects. They have been used in patients with steroid-refractory acute GVHD (aGVHD), but their relevance as a therapeutic agent targeting aGVHD has still to be defined. In this case series, we report 13 patients with steroid-refractory aGVHD who received BM-derived MSC expanded in platelet lysatecontaining medium from unrelated HLA disparate donors. MSC were characterized by their morphological, phenotypical and functional properties. All tested preparations suppressed the proliferation of in vitro activated CD4 þ T cells. MSC were transfused at a median dosage of 0.9 Â 10 6 /kg (range 0.6-1.1). The median number of MSC applications was 2 (range 1-5). Only two patients (15%) responded and did not require any further escalation of immunosuppressive therapy. Eleven patients received additional salvage immunosuppressive therapy concomitant to further MSC transfusions, and after 28 days, five of them (45%) showed a response. Four patients (31%) are alive after a median follow-up of 257 days, including one patient who initially responded to MSC treatment. In our patient cohort, response to MSC transfusion was lower than in the series reported earlier. However, our experience supports the potential efficacy of MSC in the treatment of steroid-refractory aGVHD.
Introduction
Acute graft-versus-host-disease (aGVHD) is a frequent complication after allogeneic hematopoietic stem cell transplantation (HCT) or donor lymphocyte infusion and remains a major cause of morbidity and mortality. Firstline treatment is based on corticosteroids, and the rate of durable responses varies between 50 and 80%, depending on initial severity. 1 In case of failure after corticosteroid treatment, different therapeutic options have been introduced as second-or third-line strategies. According to the pathophysiology of aGVHD, most pharmacological compounds try to inhibit T-cell activation and thereby aim to restore donor-host immunotolerance. Several studies have shown efficacy for cytostatic drugs preferentially targeting lymphocytes (for example, MTX, pentostatin), for antibodies targeting the cytokine effector pathway (for example, infliximab, etanercept) or specific T-cell antigens (for example, antithymocyte globulin and alemtuzumab). 2 However, prognosis for corticosteroid non-responders remains disappointing with a 1-year survival of only 30%. 1 Mesenchymal stem cells are multipotent adult stem cells capable of generating osteoblasts, myoblasts, chondroblasts, adipocytes and stromal cells. 3 MSC have recently been shown to mediate immunomodulatory properties in vitro, interacting with cellular components of the immune system and inducing a shift from pro-to anti-inflammatory cytokines. 4 By inhibiting T-cell proliferation after stimulation by alloantigens and mitogens and by preventing the activity of cytotoxic T cells, MSC may become a useful tool in steroid-refractory aGVHD. 5 So far, MSC have been clinically applied to facilitate engraftment in HCT and to prevent and treat aGVHD.
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Materials and methods
Patient characteristics
Between March and December 2007, 13 consecutive patients with steroid-refractory aGVHD after allogeneic HCT received third-party MSC within a compassionate use program. Patient characteristics are summarized in Table 1 . Median age at transplantation was 58 years (range 21-69). All patients received PBSC (4 from a sibling donor, 9 from an unrelated donor) after varying reduced-intensity conditioning regimes. All patients with multiple myeloma, CLL, non-Hodgkin's lymphoma, ALL and one patient (UPN 1513) with AML were transplanted because of relapse of the underlying disease after completing standard therapy (including autologous SCT in patients with multiple myeloma). Patients with ALL (UPN 1524) and AML (UPN 1513), respectively, had received re-induction chemotherapy directly before allogeneic HCT. One patient with acquired severe aplastic anemia had failed to respond to an initial course of immunosuppressive therapy with CsA and antithymocyte globulin. Patients with high-risk (defined by either cytogenetic changes or course of the disease) myelodysplastic syndrome and myeloproliferative syndrome/myelodysplastic syndrome received allogeneic HCT without preceding therapy. The second patient with AML (UPN 1493) received early allogeneic HCT (immediately after the first induction chemotherapy) because of high-risk disease defined by cytogenetic changes and insufficient response to the preceding therapy.
In vivo T-cell depletion was conducted in five patients (four with antithymocyte globulin and one with alemtuzumab, respectively). Three patients had received grafts from an HLA-mismatched donor. All of them, except patient UPN 816, had received antithymocyte globulin. The median number of transfused CD34 þ cells per kg body weight was 7 Â 10 6 (range 2-9.7). The grafts contained median of 2.6 Â 10 8 CD3 þ T cells per kg (range 0.3-5.8).
GVHD grading and response criteria Nine patients developed aGVHD directly after allogeneic HCT, three after donor lymphocyte infusion and one after cessation of immunosuppressive therapy. Grading and staging of aGVHD was performed according to criteria defined by the Consensus Workshop. 16 The median time to the first symptoms of aGVHD was 29 days (range 0-61) after the causative event: 17 days after the cessation of immunosuppression (n ¼ 1), 23 days (range 0-49) after the last donor lymphocyte infusion (n ¼ 3) or 31 days (range 13-61) directly after allogeneic HCT (n ¼ 9). Eleven patients suffered from grade IV and two suffered from grade III aGVHD by the time of MSC infusion. Skin, liver and gastrointestinal (GI) tract were affected in 6, 10 and 11 patients, respectively. All patients had failed at least two immunosuppressive regimes, including steroids, as an established first-line treatment. Previous systemic treatment for aGVHD included prednisolone (n ¼ 12), methylprednisolone (n ¼ 9), infliximab (n ¼ 6), MTX (n ¼ 3) and pentostatin (n ¼ 1). All patients with GI and skin involvement received budesonide and steroid-containing externa, respectively. Further details are given in Table 2 .
Progressive or persistent symptoms despite 5 days of treatment with steroids (42 mg/kg per day prednisolone equivalent) or 48 h after escalation of steroid-concomitant immunosuppressive therapy (that is, MTX, infliximab, pentostatin) were defined as therapy-refractory aGVHD. Additional immunosuppresssive therapy was given if symptoms of aGVHD persisted or progressed 1 week after the first MSC infusion. In case of amelioration of aGVHDrelated symptoms within a week after first MSC infusion, patients were defined as MSC responders and immunosuppression was not further escalated. Re-evaluation of global response, including all immunosuppressive medication administered, was performed 28 days after first MSC transfusion. Global response criteria were defined as follows: Progressive disease in cases of increase in staging or number of affected organs and no response in cases of no changes in staging or organ involvement. Mixed response (MR) was defined as improvement in staging of one organ with no change in others; partial response (PR) was defined as a decrease in staging but no resolution of all signs; complete response (CR) included cases of resolution of all signs, and overall response (OR) included CR, PR and MR.
Risks associated with MSC treatment were fully explained to all patients and informed consent was obtained in all cases.
Vital signs were monitored during and after intravenous bolus infusion of MSC. All patients received 4 mg dimetinden and 50 mg ranitidine before MSC transfusion. MSC were isolated and expanded according to a validated production protocol within a certified clean room unit.
Bone marrow aspirates were diluted about 1:5 with PBS (Invitrogen, Karlsruhe, Germany). The mononuclear cell fraction was isolated by density gradient centrifugation Treatment of acute GVHD with MSC M von Bonin et al (900 g, 30 min, room temperature) using Biocoll solution (Biochrom, Berlin Germany; density 1077 g/l) and seeded at a density of 6 Â 10 4 -1 Â 10 5 per cm 2 into T175 cell culture flasks (Greiner, Frickenhausen, Germany). The first passage was completed 2-3 weeks after isolation. The resulting fibroblastoid adherent cells were cultivated at 37 1C at a humidified atmosphere containing 8% CO 2 . The expansion medium consisted of DME-low glucose (Invitrogen, Karlsruhe, Germany) containing human platelet lysate at a concentration of 10%. 17 The medium was replaced twice weekly. Cells were harvested at subconfluence using TrypZean (Sigma Aldrich, Steinheim, Germany; GMP grade equivalent of Trypsin). Cells at passage 1 (and thereafter) were plated at a mean density of 5 Â 10 3 /cm 2 in T175 cell culture flasks (Greiner, Frickenhausen, Germany) and were frozen in part in medium containing 10% DMSO (WAK Chemie, Steinbach, Germany) and 5% human serum albumin (HSA, Baxter, Unterschleisheim, Germany).
For clinical use or in vitro experiments, either frozen aliquots of the MSC were thawed or MSC were used directly after isolation.
Additional information concerning the growth kinetics during ex vivo expansion is provided as Supplementary Table 1 .
Platelet lysates were derived from single-donor platelet apheresis concentrates collected at our transfusion department. The platelet concentration of each product was 1 Â 10 9 platelets per ml. Aliquots of the apheresis product were frozen at À20 1C, thawed overnight and heat inactivated at 56 1C for 30 min in a water bath. For cultivation, platelet lysates of two donors were mixed after elimination of remaining platelets by centrifugation (5000 g, room temperature, 45 min) (Supplementary Table 2 ). Comparative data concerning GMP grade MSC expansion in FCS vs platelet lysate have been previously reported. 18 In vitro analysis of MSC characteristics All MSC preparations were characterized by FACS. Standard staining and analysis protocols were applied using commercial FITC-or phycoerythrin-conjugated antibodies against CD105, CD166, CDw90, CD73, CD45, CD14 and CD34 (Becton Dickinson, San Jose, CA, USA). The potential for osteogenic and adipogenic differentiation was proven by standard differentiation media (Miltenyi Biotec, Bergisch Gladbach, Germany). Clonogenicity was tested by a standard 14 d CFU-F assay (Miltenyi Biotec). Besides sterility, the parameters mentioned had to suggest viability of the individual lot before a preparation was released for an individual patient. Only MSC from CMVseronegative healthy donors were used in CMV-seronegative patients. All donors had undergone infectious disease marker testing according to the National Marrow Donor Program (NMDP) criteria. 19 Thymidine incorporation assay Blood samples were obtained from healthy donors with informed consent. PBMCs were prepared by FicollHypaque (Biochrom, Berlin, Germany) density centrifugation. Subsequently, CD4 þ T cells were isolated from PBMCs by negative depletion using immunomagnetic separation according to the manufacturer's instructions (Miltenyi Biotec). The purity of the obtained CD4 þ T cells was 493% as assessed by flow cytometric analysis. To determine whether MSC influence T-cell proliferation, irradiated MSC (1 Â 10 4 cells per well) were co-cultured with allogeneic CD4 þ T cells (1 Â 10 5 cells per well) in the presence of 1 mg per ml PHA (Sigma Aldrich, Taufkirchen, Germany) for 4 days in round-bottomed 96-well plates. Culture medium consisted of RPMI 1640 (Biochrom) supplemented with 2 mM L-glutamine, 10 mM sodium pyruvate, 1% non-essential amino acids, 100 mg per ml penicillin, 100 mg per ml streptomycin (all from Biochrom) and 10% human serum (CC pro, Neustadt, Germany). H-thymidine (1 mCi, Hartmann Analytic, Braunschweig, Germany) was added to each well for the last 18 h of culture. Cells were harvested and incorporation was determined in a beta counter (Wallac, Freiburg, Germany).
Results
In vitro characteristics of MSC All MSC lines showed osteogenic and adipogenic differentiation potential and were proven to be viable in CFU-F assays. A homogenous phenotype was confirmed by FACS with a median purity for CD105/CD166 and Cdw90/CD73 of 96.9 and 99.8%. Negativity for CD34, CD45 and CD14 was confirmed in all cases before the product was released.
To investigate the impact of MSC on the proliferation of CD4 þ T cells, irradiated MSC lines derived from four healthy donors were co-cultured with allogeneic CD4 þ T cells in the presence or absence of PHA. As expected, PHA stimulation led to an increase in incorporated radioactivity, expressed as c. Hthymidine incorporation to 11 306 ± 1332, 9029 ± 572, 12 742 ± 925 and 10 443 ± 840 c.p.m., respectively. All experiments were carried out in triplicates. As summarized in Figure 1 , all MSC lines efficiently impaired the proliferation of PHA-stimulated CD4 þ T cells.
Clinical effects
Clinical course of therapy and response are summarized in Table 2 and Figure 2 . The first MSC infusion was given at a median of 41 days (range 20-91) after transplantation, donor lymphocyte infusion or cessation of immunosuppression and 16 days after the onset of aGVHD (range 4-31). The median number of MSC transfusion was 2 (range 1-5), the median interval between each MSC application was 7 days (range [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] and the average MSC dose given was 0.9 Â 10 6 per kg body weight (range 0.6-1.1 Â 10 6 per kg body weight) (Table3 and Figure 3 ). No infusion-related toxicity was observed during or immediately after the administration of MSC.
Concomitant immunosuppressive treatment because of therapy-refractory aGVHD included infliximab (n ¼ 8),
Treatment of acute GVHD with MSC M von Bonin et al prednisolone (n ¼ 5), pentostatin (n ¼ 4), methylprednisolone (n ¼ 3), extracorporeal photopheresis (n ¼ 3) and alemtuzumab (n ¼ 1). Only two patients (15%) did not need further escalation of immunosuppression after the first MSC transfusion. Four patients (31%) died within a period of 28 days after the first MSC transfusion. Reasons for death were pneumonia (n ¼ 2), diffuse alveolar hemorrhage (n ¼ 1) and liver failure (n ¼ 1), the latter probably related to GVHD. During the whole observation period, five more patients died: two patients died because of organ toxicity and infection (liver toxicity and encephalitis), and three patients succumbed to GVHD-associated problems (liver failure, microangiopathy and paralytic ileus). At the time of the report, four patients (31%) are still alive: two without any evidence of GVHD and the other two with chronic GVHD of the GI tract. The median follow-up for all patients is 185 days (range 55-692) after allogeneic HCT and 92 days (range 7-261) after first MSC infusion, respectively. The median follow-up for the patients who are still alive is 257 days (range 185-692) after allogeneic HCT and 207 days (range 116-261) after first MSC infusion. Until now, none of the surviving patients has experienced relapse of the underlying disease.
Global overall response, 28 days after first MSC infusion was 54% (n ¼ 7), including the two patients who responded immediately within a week after first MSC infusion. Global OR was composed of one CR, one PR and five MR (39%). With regard to initially affected organs, improvement (CR and PR) in skin, liver or GI tract involvement was observed in three (50%), five (50%) and four (36%) cases, respectively. In patients with primary skin, liver and/or GI tract involvement, the global OR (CR, PR and MR) was 33% (n ¼ 2), 60% (n ¼ 6) and 64% (n ¼ 7), respectively. The results are shown in Table 4 .
Three of the survivors (n ¼ 4) responded to the initial treatment, including one CR and two MR. Within this small-sized cohort, no correlation between underlying disease, graft source, donor type or HLA-match grade and the response to MSC therapy could be identified.
Discussion
In our cohort, only two patients (15%) responded immediately and did not require re-escalation of immunosuppression. OR, 28 days after first MSC infusion, including all immunosuppression administered, was 54%. The largest series reporting MSC as therapy for GVHD, which has been fully published, contained nine patients, including one with extensive chronic GVHD. 12 OR in patients with aGVHD was 75%, including five patients with CR. The improved response when compared with our cohort can not only be explained in part by differences in the patient's characteristics, but might be also related to differences in MSC application. In both groups, BM derived MSC were used but the donors differed. All our patients received MSC from unrelated mismatched donors, whereas only four patients of the other series obtained third-party MSC (four patients received MSC at least once from haploidentical donors, twice from HLA-identical Treatment of acute GVHD with MSC M von Bonin et al siblings). Because anti-FCS antibodies with uncertain clinical significance could be detected in patients after receiving MSC that were expanded in vitro using FCS, 20 we decided for safety reasons to replace FCS by platelet lysates. 17 In addition, compared with our series, the MSC dosage tended to be higher with a median of 1 Â 10 6 /kg (range 0.7-9 Â 10 6 per kg) and nine patients received only one or two MSC infusions in our cohort.
Another publication reported a complete disappearance of GVHD symptoms in five of six patients (83%) after receiving adipose tissue-derived MSC. 7 Although one might speculate that the origin of MSC and the serum source for expansion could impact on the anti-inflammatory and immunosuppressive effects of MSC, in vitro data suggest that the cells used in our study have functional activity. On the other hand, there is a large interindividual variability between MSC from different donors, and in part the variations between the studies can also be explained by differences in the time point of application and number of transfused cells.
Further controlled studies will hopefully define the optimal source, appropriate timing, cell dosing and potential response predictors in patients receiving MSC as a salvage therapy for refractory aGVHD.
